346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Bibliographic Details
Main Authors:	Christian Poehlein, Joseph Burgents, Christian Gratzke, Cuizhen Niu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment
by: A. Stenzl, et al.
Published: (2020-07-01)

KEYNOTE-641 phase 3 study of pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer
by: A. Stenzl, et al.
Published: (2020-07-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
by: Kenrick Ng, et al.
Published: (2020-06-01)

Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study
by: F. Saad, et al.
Published: (2020-07-01)

Increasing the age of brain: Effect of Androgen Deprivation Therapy (ADT) exposure on brain and cognition
by: A.C. Plata Bello, et al.
Published: (2020-07-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: S. Feyerabend, et al.
Published: (2020-07-01)

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)
by: R. McDermott, et al.
Published: (2020-07-01)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
by: Tobias Engel Ayer Botrel, et al.
Published: (2016-01-01)

Bone mineral density loss on long-term androgen-deprivation therapy (ADT) for the prostate cancer patients in Japan
by: Yu Ogawa, et al.
Published: (2015-06-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
by: Ying Cheng, MD, et al.
Published: (2021-10-01)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
by: Yiyi Chen, et al.
Published: (2020-07-01)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01)

The effect on quality of life of androgen deprivation therapy (ADT) combined with local external prostate radiotherapy in patients with primary metastatic prostate cancer, results from the HORRAD trial
by: L.M.S. Boevé, et al.
Published: (2020-07-01)

Inhibition steroid sulfatase suppresses androgen signaling and improves response to enzalutamide
by: A. Gao, et al.
Published: (2020-07-01)

Keynotes
Published: (2016-01-01)

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)
by: Ted A. Skolarus, et al.
Published: (2018-11-01)

HSPC300 and its role in neuronal connectivity
by: Gautreau Alexis, et al.
Published: (2007-09-01)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
by: Lu Si, et al.
Published: (2019-06-01)

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
by: Aaron Scott, et al.
Published: (2020-11-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

<i>DFNA5</i> (<i>GSDME</i>) c.991-15_991-13delTTC: Founder Mutation or Mutational Hotspot?
by: Kevin T. Booth, et al.
Published: (2020-05-01)

Flow Dynamics and HSPC Homing in Bone Marrow Microvessels
by: M. Gabriele Bixel, et al.
Published: (2017-02-01)

Keynote Speech
by: Windchy, Eli
Published: (2018)

Keynote Abstract
by: Mohd Dato’ Sabarudin, et al.
Published: (2016-01-01)

Keynote Lectures
Published: (2004-01-01)

Inflammation-Induced HSPC Dysfunction: Towards a Better Understanding of the Role of MAVS, ASC, and Caspase-1 in HSPC Dysfunction and Bone Marrow Failure
by: David, Dylan Naitraj
Published: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Inge Marie Svane, et al.
Published: (2020-07-01)

Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3
by: J.M. Piulats, et al.
Published: (2020-07-01)

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
by: Cattan, S., et al.
Published: (2022)

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
by: Zhe Hong, et al.
Published: (2021-07-01)

Studying the subunits interaction of yeast Glu-AdT
by: Chao-Hui Tseng, et al.
Published: (2010)

Keynote: The Joy of Research
by: Sommerall, D'Ann
Published: (2021)

KEYNOTE: THE BIOGRAPHY OF OBJECTS
by: C. Greco
Published: (2019-05-01)

Keynote Speaker Abstracts
by: Isnansetyo Alim
Published: (2020-01-01)

Soluble ADT and diamine-terphenyl derivatives for OTFT material
by: Peng-Yi Huang, et al.
Published: (2007)

Information Allocation for Transport Switched Systems With ADT Method
by: Xiaoli Jiang, et al.
Published: (2020-01-01)

ADT: Object Tracking Algorithm Based on Adaptive Detection
by: Yue Ming, et al.
Published: (2020-01-01)